Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

Vittorio Stefoni, Alessandro Broccoli, Lapo Alinari, Valentina Ambrosini, Enrico Derenzini, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Enrica Marchi, Cinzia Pellegrini, Federica Quirini, Pier Luigi Zinzani, Michele Baccarani

Blood (2009) 114 (22): 1659.

https://doi.org/10.1182/blood.V114.22.1659.1659

Published: 2009

Journal Articles

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, Monica Tani, Alessandro Broccoli, Enrico Derenzini, Alessandro Pulsoni, Amalia De Renzo, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Cinzia Pellegrini, Vittorio Stefoni, Michele Baccarani

Blood (2009) 114 (22): 3743.

https://doi.org/10.1182/blood.V114.22.3743.3743

Published: 2009

Journal Articles

A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Pier Luigi Zinzani, Mariapaola Fina, Monica Tani, Vittorio Stefoni, Letizia Gandolfi, Alessandro Broccoli, Cinzia Pellegrini, Enrico Derenzini, Giuseppe Rossi, MD, Emanuele Angelucci, Gianluca Gaidano, Maria Concetta Petti, Maurizio Martelli, Umberto Vitolo, Stefano Fanti, Michele Baccarani

Blood (2009) 114 (22): 2720.

https://doi.org/10.1182/blood.V114.22.2720.2720

Published: 2009

Journal Articles

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Pier Luigi Zinzani, MD, PhD, Vittorio Stefoni, MD, Valentina Ambrosini, MD, Enrico Derenzini, MD, Gerardo Musuraca, MD, Enrica Marchi, MD, Lapo Alinari, MD, Mariapaola Fina, MD, Monica Tani, MD, Cinzia Pellegrini, MD, Stefano Fanti, MD, Michele Baccarani, MD

Blood (2007) 110 (11): 216.

https://doi.org/10.1182/blood.V110.11.216.216

Published: 2007

Journal Articles

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Gerardo Musuraca, MD, Vittorio Stefoni, MD, Enrica Marchi, MD, Mariapaola Fina, MD, Michele Baccarani, MD, PhD

Blood (2006) 108 (11): 2462.

https://doi.org/10.1182/blood.V108.11.2462.2462

Published: 2006

Journal Articles

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Stefano Fanti, MD, Vittorio Stefoni, MD, Gerardo Musuraca, MD, Paolo Castellucci, MD, Enrica Marchi, MD, Mariapaola Fina, MD, Michele Baccarani, MD,PhD

Blood (2006) 108 (11): 2431.

https://doi.org/10.1182/blood.V108.11.2431.2431

Published: 2006

Journal Articles

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Stefano Fanti, MD, Gerardo Musuraca, MD, Alessio Perrotti, MD, Umberto Vitolo, MD, Mariapaola Fina, MD, Barbara Botto, MD, Enrica Marchi, MD, Giulia Benevolo, MD, Vittorio Stefoni, MD, Michele Baccarani, MD,PhD

Blood (2006) 108 (11): 2478.

https://doi.org/10.1182/blood.V108.11.2478.2478

Published: 2006

Journal Articles

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, Monica Tani, Vittorio Stefoni, Lapo Alinari, Enrica Marchi, Mariapaola Fina, Michele Baccarani

Blood (2005) 106 (11): 4763.

https://doi.org/10.1182/blood.V106.11.4763.4763

Published: 2005

Journal Articles

Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.

Pier Luigi Zinzani, Monica Tani, Vittorio Stefoni, Lapo Alinari, Enrica Marchi, Mariapaola Fina, Michele Baccarani

Blood (2005) 106 (11): 4764.

https://doi.org/10.1182/blood.V106.11.4764.4764

Published: 2005

Journal Articles

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Pier Luigi Zinzani, Monica Tani, Vittorio Stefoni, Lapo Alinari, Enrica Marchi, Mariapaola Fina, Michele Baccarani

Blood (2005) 106 (11): 4765.

https://doi.org/10.1182/blood.V106.11.4765.4765

Published: 2005

NARROW

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Follicular Lymphoma (FL) Patients.

Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only